EDMUND HARRIGAN

CIK 1177917 · last filed 2026-06-10

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.38M

Companies

5

Total Filings

64

Lifetime Open-Market Net

-$4.46M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY Director 22,764 $108.53 $2.47M $0 34 2026-06-10
ACAD Director 43,148 $21.09 $910.0K $33.0K 14 2026-06-01
PhaseBio Pharmaceuticals Inc (PHAS) Delisted Director 6,000 $0.07 $421 $24.7K 6 2022-05-20
Karuna Therapeutics, Inc. (KRTX) Delisted Director 55,163 $329.83 $18.19M -$4.52M 6 2020-08-14
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Director $0.07 $0 3 2019-06-14

Recent Filings · Page 3 of 7

64 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-05-19 Exer (M) +3,750 $0
2023-04-04 INCY Grant (A) +326 $23.6K EDGAR
2023-01-04 INCY Grant (A) +302 $24.3K EDGAR
2022-10-20 INCY Grant (A) +165 $11.5K EDGAR
2022-10-04 INCY Grant (A) +250 $16.7K EDGAR
2022-07-01 INCY Grant (A) +236 $17.9K EDGAR
2022-06-17 INCY Grant (A) +2,144 $0 EDGAR
2022-06-09 ACAD Grant (A) $0 EDGAR
2022-05-20 PhaseBio Pharmaceuticals Inc (PHAS) Delisted Grant (A) $0 EDGAR
2022-04-04 INCY Grant (A) +240 $19.1K EDGAR
Showing 2130 of 64
Page 3 of 7
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.